Bancel letter showcases Moderna’s focus on mRNA vaccines

Moderna giving antiviral vaccines top billing in its sprawling mRNA pipeline reflects the growing consensus that the modality’s biggest near-term value lies in its potential to stoke immune responses.

With 21 candidates spanning six treatment paradigms and more than a dozen disease indications, Moderna’s pipeline breadth has been widely viewed as a key differentiating factor (see “Moderna’s

Read the full 568 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers